Labcorp to offer risk-scoring test for people with advanced liver fibrosis due to nash

Burlington, n.c.--(business wire)--for the millions of people in the united states living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant. labcorp (nyse: lh), a leading global life sciences company, is making this possible by offering the enhanced liver fibrosis (elf™) test. developed by siemens healthineers, the physician-ordered blood test helps assess the risk of disease progr
LH Ratings Summary
LH Quant Ranking